Michael Chambers, Interim Chief Executive Officer

Michael Chambers

Michael founded Aldevron in 1998 with John Ballantyne. He led Aldevron’s efforts to acquire GENOVAC (Freiburg, Germany) in 2004 and to establish Aldevron Madison (Madison, WI) in 2009. Michael is well networked in the biotechnology industry and leads Aldevron in technical and strategic directions. He serves on numerous boards and committees in organizations like Altravax, Agathos, and the American Society of Gene and Cell Therapy (ASGCT). Michael is dedicated to applying lean manufacturing and continuous improvement strategies to the biotechnology CDMO Market space.

Robert Whalen, DSc, Chief Scientific Officer

Robert Whalen

Dr. Whalen has over 15 years experience in the biotech industry as a consultant and senior manager. Before co-founding Altravax in 2009, he was Director, Infectious Diseases at Maxygen, Inc. where he oversaw numerous vaccine projects dealing with vaccines to hepatitis A and B, HIV-1, influenza, malaria, encephalitic alphaviruses, flaviviruses, and various biodefense targets. He is an expert in the application of directed molecular evolution to the discovery and optimization of vaccines, and has broad experience in molecular biology, biochemistry, cell biology, developmental biology, physiology, immunology, and vaccinology. From 1972-1995, Robert was a research scientist and group leader in the Department of Molecular Biology at the Pasteur Institute in Paris, France. Beginning in 1993 he made pioneering contributions to the emerging field of DNA vaccines. He is the author of over 120 scientific papers, reviews and book chapters. He holds degrees in chemistry from Harvard University (M.A., 1974) and The Pennsylvania State University (B.S., 1970).

Janelle Muranaka, Director of Operations

Janelle Muranaka

As Director of Operations at Altravax Janelle has been instrumental in the launch of the Company’s Acclivity service division offering client’s custom protein optimization programs utilizing directed evolution technologies. Her responsibilities include development of project proposals and budgets for service activities, interacting with clients, managing the scientific team and R&D programs, as well as ensuring compliance of all necessary safety, hazmat, and government regulations. Previous positions at Altravax include Operations Manager and Research Associate, where she was involved in many of the Company’s vaccine discovery programs using MolecularBreeding™ directed evolution. Additionally, Janelle spent time as a Research Assistant in the molecular engineering team at Codexis optimizing enzymes and was a member of the vaccine group at Maxygen which spun off as Altravax in 2010.